Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

A Delaware judge correctly interpreted transcatheter aortic valve-replacement device patents that were asserted against ...

Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient enrollment in its Protect the Head to Head (ProtectH2H) ...

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart compa ...

Edwards Lifesciences Corp (EW) has reached a new 52-week high, with its stock price climbing to 83.02 USD. According to InvestingPro data, the company maintains strong financial health with a "GOOD" ...

Do all heart valve replacements need open-heart surgery? Let's know the new techniques that could change everything ...